Introduction

Globally, breast cancer is the most frequently diagnosed and the leading cause of cancer death in women. In 2013, the World Health Organization’s International Agency for Research on Cancer noted a sharp rise in breast cancer worldwide, an increase in more than 20% since 2008. The economic and social burden is great, as breast cancer represents one in four of all cancers in women (1,2). The current standard of treatment for breast cancer is surgery. Surgical considerations include the staging of the cancer with the Tumor, Node, Metastases system and the size of the tumor relative to the remaining breast tissue. For patients with non-metastatic breast cancer, stratification is generally to either early stage, clinical stage I, IIA, or IIB (T2N1) or locally advanced breast cancer, clinical stage IIB (T3N0) to IIIC (3). Options for surgery range from lumpectomy, simple resection of the tumor and margin of healthy breast tissue, to total mastectomy with sentinel node biopsy for axillary staging. Although decision-making is prioritized to obtain best oncological outcomes, factors such as breast conservation and cosmetic outcomes are also important considerations with breast cancer treatment.

Surgical resection has been the standard of treatment of primary solid tumors localized to organs such as the lung, colon, and breast. New research in radiofrequency ablative therapy has brought light to alternative noninvasive methods (4). Nonsurgical options have a number of benefits, including decreased risk of complications from anesthesia, improved cosmesis, and shortened recovery time. Many patients have co-morbidities and poor functional status, which increase risk of post-surgical complications including bleeding, stroke, and/or death (5). In these cases, a nonsurgical option may decrease the morbidity and mortality of patients. Improved cosmesis, such as breast conservation and minimal scarring, is another
potential benefit from less invasive breast cancer treatment. Unlike other solid tumors, breast cancer is unique in the importance of decreasing the deformity of the surgical procedure. In a 2000 retrospective study by Al-Ghazal et al., it was concluded that patient satisfaction with cosmetic outcomes after breast cancer therapy was critical to psychological well-being and quality of life (6).

Radiofrequency ablation (RFA) is a widely studied minimally invasive technique. It is used as treatment and palliation in a number of primary and secondary solid tumors including hepatocellular carcinoma, non-small cell lung cancer, and renal neoplasms (7). RFA utilizes a radiofrequency electrode and image guidance, usually CT or ultrasound, to heat and coagulate targeted tissue (8). The thermal energy is localized to achieve necrosis of only malignant tissue with minimal destruction of the surrounding healthy cells. RFA use in breast cancer is a developing area of research, and particularly exciting due to the recent trend toward less invasive breast cancer treatments. There have been a number of published studies over the last decade which explore the feasibility of minimally invasive techniques in breast cancer treatment. In this review paper, we will discuss the most recent data on radiofrequency ablation and examine the current methods, outcomes, complications, and limitations of RFA in breast cancer therapy.

Results

English-language papers on RFA use in breast cancer are summarized in Table 1. Most of the articles are small feasibility studies involving invasive breast tumors, with the N representing the number of tumors. The majority of studies were from single institution populations, however, one multicenter study was included in this review (21). A few studies included are follow-up papers from previous studies (25,29,31). Due to the technical limitations of RFA, all tumors were selected on basis of size. Although studies had various upper limits, the average tumor size was relatively comparable at 1-2 cm. Some studies reported only tumor staging; therefore no average tumor size was obtained (9,19). Since RFA techniques are both operator and instrument dependent, we included the type of RFA electrode utilized. The two most common electrodes used were Cool-Tip by Covidien and Starburst by Angiodynamics. In this review, complete ablation is defined as the absence of viable tumor cells in the resected specimen as verified by immunohistochemistry, tissue biopsy, and/or imaging. The table shows both the number and percentage of complete ablation reported by each study. Surgical resection usually occurred after RFA was applied in vivo. In three cases, surgical resection occurred first, and RFA therapy was later applied in vitro (15,33,35). In a number of cases, definitive surgical resection was not performed due to age of patient or co-morbidities that did not allow for mass excision (16,17,19,20,26,28,32,34). In these cases, tissue may only be obtained via ultrasound guided core biopsy or mammmotome biopsy. Skin burn and mass formation at the electrode site were the major RFA complications reported by the studies, although this occurred in only a small number of patients.

Discussion

Patient selection criteria

RFA utilizes local thermal energy to induce coagulative necrosis, which limits the size of tumors eligible for ablation. The participants were therefore highly selected based on patient factors, features on initial biopsy, and imaging. Selective criteria between studies differed greatly. For instance, patients with prior neoadjuvant chemotherapy were excluded from some studies; while in others, it was the near majority of the patient population (34). Others made amendments to their criteria to include patients receiving neoadjuvant chemotherapy later in the study (13). In addition, many studies excluded patients on the basis of features found on biopsy such as signs of ductal carcinoma in situ and lobular type carcinoma. Some studies also excluded patients on the basis of imaging findings such as masses with unclear borders, extensive microcalcifications, and tumors within 1 cm of the skin (10,29). Since thermal ablation is known to change the characteristics of tumor marker expression, estrogen, progesterone, and HER2 receptor status, grade, histology, and need for adjuvant chemotherapy had to be known prior to RFA therapy (11,13,18,22). Studies with planned definitive resection excluded patients with medical contraindications to surgery, such as sensitivity to anesthesia and coagulopathy. However, there were also a number of studies where the population of interest was specifically elderly patients who refused surgery and/or had co-morbid conditions that precluded them from surgical interventions (16,19,34). Due to strict and varying nature of the patients selected for the studies described in this review, the application of RFA therapy may not be feasible in a significant portion of breast cancer patients.
Table 1 Summary of studies on radiofrequency ablation and breast cancer

<table>
<thead>
<tr>
<th>Study references</th>
<th>N</th>
<th>Tumor size range (cm)</th>
<th>Average tumor size (cm)</th>
<th>RFA electrode</th>
<th>Complete ablation, n [%]</th>
<th>Resection</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Izzo et al., 2001 (9)</td>
<td>26</td>
<td>0.7-3.0</td>
<td>1.8</td>
<td>LeVeen</td>
<td>25 [96]</td>
<td>Immediate</td>
<td>1 skin burn</td>
</tr>
<tr>
<td>Burak et al., 2003 (10)</td>
<td>10</td>
<td>0.8-1.6</td>
<td>1.2</td>
<td>Multiarray</td>
<td>9 [90]</td>
<td>Delay (1-3 weeks)</td>
<td>Minimal breast ecchymosis</td>
</tr>
<tr>
<td>Hayashi et al., 2003 (11)</td>
<td>22</td>
<td>0.5-2.6</td>
<td>0.9</td>
<td>Starburst</td>
<td>20 [86]</td>
<td>Delay (1-2 weeks)</td>
<td>1 skin burn, 2 minimal bruising</td>
</tr>
<tr>
<td>Singletary et al., 2003 (12)</td>
<td>29</td>
<td>&lt;2.0</td>
<td>–</td>
<td>Starburst</td>
<td>25 [86]</td>
<td>Immediate</td>
<td>1 skin burn</td>
</tr>
<tr>
<td>Fornage et al., 2004 (13)</td>
<td>21</td>
<td>0.6-2.0</td>
<td>1.2</td>
<td>Starburst</td>
<td>21 [100]</td>
<td>Immediate</td>
<td>None</td>
</tr>
<tr>
<td>Noguchi et al., 2006 (14)</td>
<td>10</td>
<td>0.5-2.0</td>
<td>1.1</td>
<td>Starburst</td>
<td>10 [100]</td>
<td>Immediate</td>
<td>None</td>
</tr>
<tr>
<td>Klimberg et al., 2006 (15)</td>
<td>41</td>
<td>0.1-4.0</td>
<td>1.6</td>
<td>Starburst</td>
<td>31 [75]</td>
<td>Lumpectomy followed by RFA</td>
<td>2 skin burns, 1 delayed healing in diabetic</td>
</tr>
<tr>
<td>Susini et al., 2007 (16)</td>
<td>3</td>
<td>1.0-1.3</td>
<td>1.16</td>
<td>Cool-Tip</td>
<td>3 [100]</td>
<td>Delay—core biopsies</td>
<td>None</td>
</tr>
<tr>
<td>Oura et al., 2007 (17)</td>
<td>52</td>
<td>0.5-2.0</td>
<td>1.3</td>
<td>Cool-Tip</td>
<td>52 [100]</td>
<td>Delay—cytological evaluation</td>
<td>1 skin burn, mass formation at site of RFA</td>
</tr>
<tr>
<td>Khatri et al., 2007 (18)</td>
<td>15</td>
<td>0.8-1.5</td>
<td>1.28</td>
<td>Cool-Tip</td>
<td>14 [93]</td>
<td>Immediate</td>
<td>2 skin puckering, 1 wound infection</td>
</tr>
<tr>
<td>Marcy et al., 2007 (19)</td>
<td>5</td>
<td>cT1-2N0M0</td>
<td>–</td>
<td>Elektrotom</td>
<td>4 [80]</td>
<td>Delay—core biopsies</td>
<td>4/4 firm mass 4 cm × 5 cm, 1 abscess</td>
</tr>
<tr>
<td>Earashi et al., 2007 (20)</td>
<td>17</td>
<td>0.5-2.4</td>
<td>1.1</td>
<td>Starburst</td>
<td>17 [100]</td>
<td>Immediate</td>
<td>None</td>
</tr>
<tr>
<td>Earashi et al., 2007 (20)</td>
<td>7</td>
<td>0.7-2.0</td>
<td>1.1</td>
<td>Starburst</td>
<td>7 [100]</td>
<td>Delay—mammotome excision</td>
<td>None</td>
</tr>
<tr>
<td>Medina-Franco et al., 2008 (21)</td>
<td>25</td>
<td>0.9-3.8</td>
<td>2.08</td>
<td>Elektrotom</td>
<td>19 [76]</td>
<td>Immediate</td>
<td>3 skin burns</td>
</tr>
<tr>
<td>Imoto et al., 2009 (22)</td>
<td>30</td>
<td>0.9-2.4</td>
<td>1.7</td>
<td>LeVeen</td>
<td>27 [93]</td>
<td>Immediate</td>
<td>2 skin burns, 7 muscle burns</td>
</tr>
<tr>
<td>Manenti et al., 2009 (23)</td>
<td>34</td>
<td>1.65-1.96</td>
<td>1.89</td>
<td>Cool-Tip</td>
<td>33 [97]</td>
<td>Delay (4 weeks)</td>
<td>1 skin burn</td>
</tr>
<tr>
<td>Wiksell et al., 2010 (24)</td>
<td>31</td>
<td>0.6-1.5</td>
<td>1.13</td>
<td>Neodynamics</td>
<td>26 [84]</td>
<td>Immediate</td>
<td>1 pneumothorax, 2 muscle burns, 1 skin burn</td>
</tr>
<tr>
<td>Motoyoshi et al., 2010 (25)</td>
<td>17</td>
<td>0.5-2.1</td>
<td>1.5</td>
<td>Starburst</td>
<td>14 [82]</td>
<td>Immediate</td>
<td>2 distant mets (f/u 49 months)</td>
</tr>
</tbody>
</table>

Table 1 (continued)
Nevertheless as the median sizes of the breast tumor are decreasing due to population screening increasing number of patients may be eligible.

**RFA devices**

Studies in this review utilized the RFA electrode listed in Table 1. These RFA instruments were originally developed for non-breast cancer solid tumors and vary in both the shape and size of needle and array.

The Covidien Cool Tip was developed for soft tissue tumors. It involves a system of straight needles which when used in combination can ablate an area of up to 6.7 cm × 6.5 cm. It uses a 20.5-gauge needle with lengths varying from 10-25 cm. The cool tip system uses water during the process to reduce impedance of the tissues during ablation (36).

Integra makes the Elektrotom HiTT and like the Cool tip has a saline infused electrode and developed for liver tumor ablation. This comes in a variety of straight needle lengths and electrodes. It is compatible with all imaging modalities (37).

The LeVeen by Boston Scientific RFA device was designed for the ablation of liver tumors with a straight needle with umbrella shaped array. Lengths range from 12-25 cm with array diameters from 2-5 cm (38).

Starburst by Angiodynamics was developed for soft

### Table 1 (continued)

<table>
<thead>
<tr>
<th>Study references</th>
<th>N</th>
<th>Tumor size range (cm)</th>
<th>Average tumor size (cm)</th>
<th>RFA electrode</th>
<th>Complete ablation, n [%]</th>
<th>Resection</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motoyoshi et al., 2010 (25)b</td>
<td>17</td>
<td>0.5-2.0</td>
<td>1.2</td>
<td>Starburst</td>
<td>8 [50]</td>
<td>Delay (30-202 days)</td>
<td>1 distant mets</td>
</tr>
<tr>
<td>Brkljacic et al., 2010 (26)</td>
<td>7</td>
<td>1.0-2.7</td>
<td>–</td>
<td>Saline infusion</td>
<td>6 [86]</td>
<td>Delay – core biopsies</td>
<td>None</td>
</tr>
<tr>
<td>Kinoshita et al., 2011 (27)</td>
<td>49</td>
<td>0.5-3.0</td>
<td>1.70</td>
<td>Cool-Tip</td>
<td>37 [76]</td>
<td>Immediate</td>
<td>2 skin burns, 3 muscle burns</td>
</tr>
<tr>
<td>Yamamoto et al., 2011 (28)</td>
<td>30</td>
<td>0.5-1.9</td>
<td>1.28</td>
<td>Cool-Tip</td>
<td>28 [93]</td>
<td>Delay – mammotome biopsies</td>
<td>3 skin burns, 1 mastitis</td>
</tr>
<tr>
<td>Ohtani et al., 2011 (29)</td>
<td>9</td>
<td>0.5-1.8</td>
<td>1.3</td>
<td>Cool-Tip</td>
<td>4 [44]</td>
<td>Immediate</td>
<td>None</td>
</tr>
<tr>
<td>Ohtani et al., 2011 (29)</td>
<td>32</td>
<td>0.5-1.8</td>
<td>1.3</td>
<td>Cool-Tip</td>
<td>32 [100]</td>
<td>Delay (1-2 months)</td>
<td>1 skin burn</td>
</tr>
<tr>
<td>Vilar et al., 2012 (30)</td>
<td>14</td>
<td>1.0-2.5</td>
<td>1.76</td>
<td>LeVeen</td>
<td>7 [50]</td>
<td>Delay (4 weeks)</td>
<td>1 fistula, 1 skin burn</td>
</tr>
<tr>
<td>Noguchi et al., 2012 (31)b</td>
<td>19</td>
<td>0.5-2.0</td>
<td>1.3</td>
<td>Starburst</td>
<td>10 [56]</td>
<td>Delay (24-202 days)</td>
<td>1 skin dimple, 9 persistent lump</td>
</tr>
<tr>
<td>Yoshinaga et al., 2013 (32)</td>
<td>14</td>
<td>0.6-2.0</td>
<td>1.2</td>
<td>Cool-Tip</td>
<td>6 [100]</td>
<td>6 immediate, 8 core biopsy</td>
<td>1 skin burn</td>
</tr>
<tr>
<td>Mackey et al., 2012 (33)</td>
<td>16</td>
<td>&lt;3.0</td>
<td>0.775</td>
<td>Unknown</td>
<td>16 [100]</td>
<td>Lumpectomy followed by RFA</td>
<td>1 re-excision</td>
</tr>
<tr>
<td>Palussiere et al., 2012 (34)</td>
<td>21</td>
<td>&lt;3.0</td>
<td>–</td>
<td>LeVeen</td>
<td>17 [81]</td>
<td>Most none, biopsy if indicated</td>
<td>4 recurrences, palpable mass in 18/21</td>
</tr>
<tr>
<td>Kreb et al., 2013 (35)c</td>
<td>20</td>
<td>0.4-1.5, 0.7-2.3</td>
<td>0.98, 1.2</td>
<td>Cool-tip</td>
<td>17 [85]</td>
<td>Prior to RFA</td>
<td>None</td>
</tr>
</tbody>
</table>

---

*a*, Izzo *et al*. report cT1-T2; *b*, one patient refused excision; *c*, Kreb *et al.* reported pre-operative and post-operative tumor sizes (shown in table respectively). Abbreviations: RFA, radiofrequency ablation; mets, metastasis; f/u, follow-up.
tissue, liver and bone. It is able to curve up to 90 degrees with an umbrella deployment of electrodes, is MRI compatible with a retractable/deployable needle and can ablate up to a 5 cm diameter from the tip (39).

Radioablation has shown good success in homogenous tissues, such as the liver (40). Since the process of RFA coagulates tumors at different rates depending on the amount of glandular tissue, skin burns are common complications. Breast cancer therapy may benefit from the development of an instrument that can adapt to the heterogeneous nature of breast tissue. Another limitation of RFA therapy is the size of the lesion treated is limited by electrode. Currently, there are no RFA electrodes FDA approved specifically for breast. The general approval is for soft tissue ablation which includes breast.

Ablation success

The method of assessing complete ablation is not mentioned in Table 1. The studies used various methods including immunohistochemistry staining, cytological evaluation, core biopsies, mammotome biopsies, and fine needle aspiration. Most commonly, hematoxylin and eosin (H&E) staining was used to determine the margins of the tumor and nicotinamide adenine dinucleotide (NADH) diaphorase stains were used to detect any viable tumor cells present in the surgical resection. Some studies used cytokeratin 8/18, which detects tumor necrosis seen with successful RFA treatment (10). Using these methods, the majority of the studies showed promising rates of complete ablation. Although histopathology seems to be an adequate way of determining level of ablation with feasibility studies, evaluation requires some form of tissue sampling or excision. While surgical excision and immunohistochemistry will confirm adequate treatment, core biopsies cannot check for tumor-free margins. Therefore, these methods may not be practical for use if the goal is a noninvasive therapy. In these situations, advanced imaging would be necessary for close surveillance and this can include contrast enhanced breast MRI for example. Furthermore the oncology community will need to become comfortable with radiologic assessment of complete tumor destruction (verified by well designed clinical trials) and decision for adjuvant therapy can be made from the pre-therapy core biopsy.

Imaging

The feasibility of RFA use in the treatment of breast cancer will rely largely on the continued advancement of imaging. For one, imaging is critical for the localization of the tumor itself. Many studies compared ultrasound estimates of breast tumors pre-RFA and noted significant variations with respective MRI comparison (10,11,23,30). Secondly, image-guidance is required while performing RFA in vivo to ensure correct placement of the electrode and response of the tumor during the procedure. Incomplete ablation has been linked to incorrect placement of the RFA electrode during ablation, which should be at the center of the tumor (41). Therefore, the effectiveness of RFA treatment is directly correlated to the use of imaging. Radiofrequency ablation utilizes high temperatures, which can lead to complications such as skin burns. Nahiriya et al. have found a strong link between Doppler ultrasound signal changes and tissue boiling (42). This study suggests that use of Doppler ultrasound following ablation may help to prevent complications due to RFA temperatures. Additionally, imaging is required to assess the tissue response to RFA therapy and the oncologic outcomes of the treatment in long-term follow-up. In the many studies, complete ablation was evaluated with the use of imaging and histopathology. In Palussiere et al. no definitive surgical resection was performed, therefore imaging was the only method of assessing for the successful ablation of lesions (34). Continued advances in imaging will be critical to allow accurate assessment of the ablation and for subsequent follow-up to detect recurrence.

Cosmesis

Breast conserving therapy, breast conserving surgery with adjuvant chemotherapy, has been found to be equivalent to mastectomy, but with the advantage of minimizing deformity to the breast. However, breast conserving therapy still requires negative margins and therefore, may not produce good cosmetic results in patients with less breast tissue. A major benefit of RFA utilization in breast cancer treatment is the potential for improved cosmesis with patients who have early-staged small breast cancers. A few studies evaluated the cosmetic outcomes and patient satisfaction with the procedure (17,23,31) Oura et al. reported cosmetic outcomes as excellent, good and fair, with 43/52 patients reporting excellent cosmesis (17). The major factor affecting the cosmetic results in this study was the presence of mass formation at the RFA site secondary to fat necrosis. Manenti et al. evaluated cosmesis by two surgeons not involved patient treatment, whom evaluated skin texture
and pigmentation and rated as excellent, good, acceptable, and poor (23). Overall cosmesis in this study was promising, with 28/34 patients assessed as excellent. Cosmesis may not be accurately reflected in the majority of these studies because surgical excision was used to both confirm the effectiveness of the RFA therapy, as well as ensure the current standard of care was performed. Further study is warranted to evaluate patient satisfaction and cosmetic outcomes in patients without definitive surgical resection.

**Complications/safety**

Radiofrequency ablation in other cancer therapy has been shown to have a relatively low associated risk, with morbidity between 2-10% and mortality between 0.3-0.8% (40,43). In the above studies, complications associated with RFA included skin burns, muscle burns, ecchymosis, skin puckering and mass formation secondary to fat necrosis at the RFA site. An isolated case of wound infection, mastitis, and pneumothorax were reported in three different studies (18,24,28). Distant metastases were also documented in one study (25). Overall, the safety profile of RFA therapy appears very good, with many of the common complications involving superficial injury or skin changes. In addition, many authors have developed protocols with RFA electrode use to minimize the complications noted above. Oura et al. found fewer skin burns with injection of 5% glucose, which both enlarged the distance between the tumor and skin, as well as interrupting radiofrequency to affected skin (17). Ice packs were applied to the skin in studies when the mass was more superficial to prevent burns (34). Although it appears that many of the common complications are benign skin changes undoubtedly affect the cosmesis and patient satisfaction with the procedure. In addition, a mass formation may increase anxiety of cancer recurrence for the patient. Adequate counseling should be provided prior to RFA treatment to warn patients about these potential results. Future studies may want to optimize thermoablation methods using previous protocols which haven shown success at minimizing these outcomes. As stated previously, there is no current consensus on RFA device or technique in breast cancer masses.

The main safety issue with RFA treatment involves outcomes of breast cancer recurrence and survival rates. As of now, follow up has been largely limited. The longest follow up study is with Noguchi with a mean of 60 months, which found no in-breast recurrence, but one axillary lymph node and hepatic metastasis (31). In terms of oncologic outcome, there is not enough data to conclude if RFA is a safe alternative to surgery at this time.

**Conclusions**

Radiofrequency ablation is an emerging minimally invasive therapy in small, localized breast cancer. As of now, RFA is FDA approved for use in soft tissue tumors, including breast cancer. With the potential of improved cosmesis and excellent safety profile, RFA may come to replace or compete with current surgical resection if the oncologic outcomes are comparable. Currently, no clinical trials have been conducted to directly compare RFA to the current standard of surgical resection. Comparison studies have been performed in a number of other solid tumors with encouraging results. For instance, Chadwick et al. compared RFA and surgical resection in the treatment of Barrett’s esophagus and found to be the two modalities to be equally effective (44). The limitation with Chadwick’s study, and others of its kind, is that mean follow up was not sufficient to make conclusive statements in long-term oncologic outcomes. In order to assess the role of RFA in breast cancer therapy, imaging modalities will have to advance to detect tumor resolution and monitor for recurrence. Future studies should also document hospital time, post-procedural pain, other complications associated with RFA versus surgical resection. In addition, patient satisfaction with cosmesis and level of anxiety with this novel intervention should also be reported. Ultimately, RFA will need several studies to evaluate for oncologic outcomes these studies requiring a large patient population and long interval follow up to determine disease progression.

There are currently no RFA devices specific for the treatment of breast cancers, nor consensus on how they should be used. With this evolving treatment modality, the next step would involve more studies are warranted to determine which devices work best in the area of breast versus more dense tissues such as liver and bone.

**Acknowledgements**

**Disclosure:** The authors declare no conflict of interest.

**References**


Cite this article as: Nguyen T, Hattery E, Khatri VP. Radiofrequency ablation and breast cancer: a review. Gland Surgery 2014;3(2):128-135. doi: 10.3978/j.issn.2227-684X.2014.03.05